Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ensitrelvir in Hepatic Impairment
NCT05409911Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ensitrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 7 more. Started Sep 2022; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05409911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409911.